Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, Caro RB, Kim DW, Lee JS, Cousin S, Ichihara E, Li Y, Paz-Ares L, Ono A, Sanborn RE, Watanabe N, Jose de Miguel M, Helissey C, Shu CA, Spira AI, Tomasini P, Chih-Hsin Yang J, Zhang Y, Felip E, Griesinger F, Waqar SN, Calles A, Neal JW, Baik CS, Jänne PA, Shreeve SM, Curtin JC, Patel B, Gormley M, Lyu X, Chen J, Chu PL, Mahoney J, Trani L, Bauml JM, Thayu M, Knoblauch RE, Cho BC. Besse B, et al. Among authors: ono a. J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02550-4. doi: 10.1016/j.jtho.2024.12.029. Online ahead of print. J Thorac Oncol. 2025. PMID: 39755170 Free article.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. Among authors: ono a. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
Niho S, Yoshida T, Akimoto T, Sakamaki K, Ono A, Seto T, Nishio M, Yamamoto N, Hida T, Okamoto H, Kurata T, Satouchi M, Goto K, Yamanaka T, Ohe Y. Niho S, et al. Among authors: ono a. Lung Cancer. 2020 Mar;141:64-71. doi: 10.1016/j.lungcan.2020.01.008. Epub 2020 Jan 10. Lung Cancer. 2020. PMID: 31955002 Clinical Trial.
Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer.
Kodama H, Murakami H, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ko R, Ono A, Kenmotsu H, Naito T, Matsumoto S, Goto K, Shimizu T, Gon Y, Takahashi T. Kodama H, et al. Among authors: ono a. Thorac Cancer. 2024 Jul;15(21):1665-1672. doi: 10.1111/1759-7714.15382. Epub 2024 Jun 19. Thorac Cancer. 2024. PMID: 38898747 Free PMC article.
Prognostic impact of circulating tumor cells in patients with small cell lung cancer.
Naito T, Tanaka F, Ono A, Yoneda K, Takahashi T, Murakami H, Nakamura Y, Tsuya A, Kenmotsu H, Shukuya T, Kaira K, Koh Y, Endo M, Hasegawa S, Yamamoto N. Naito T, et al. Among authors: ono a. J Thorac Oncol. 2012 Mar;7(3):512-9. doi: 10.1097/JTO.0b013e31823f125d. J Thorac Oncol. 2012. PMID: 22258473 Free article.
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.
Kodama H, Kenmotsu H, Kawabata T, Notsu A, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Takahashi T. Kodama H, et al. Among authors: ono a. Cancer Med. 2021 Nov;10(21):7503-7513. doi: 10.1002/cam4.4268. Epub 2021 Sep 29. Cancer Med. 2021. PMID: 34587359 Free PMC article.
Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.
Sekikawa M, Murakami H, Morita M, Doshita K, Miura K, Kodama H, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Kenmotsu H, Naito T, Chiba H, Takahashi T. Sekikawa M, et al. Among authors: ono a. Thorac Cancer. 2023 Dec;14(35):3475-3482. doi: 10.1111/1759-7714.15140. Epub 2023 Oct 24. Thorac Cancer. 2023. PMID: 37873674 Free PMC article.
1,454 results